Company & Sponsor Intelligence
GlaxoSmithKline
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials31
Recruiting1
Completed28
Countries10
Therapeutic footprint
adhdalzheimersdepressionepilepsyother_psychiatryout_of_scopeparkinsonsschizophrenia
Indexed studies
NCT00044278Pediatric Epilepsy Study in Subjects 1-24 Months
epilepsy · United StatesPHASE2
epilepsy · United StatesPHASE2
NCT00048360Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults
adhd · United StatesPHASE3
adhd · United StatesPHASE3
NCT01435915Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects
parkinsons · ChinaPHASE1
parkinsons · ChinaPHASE1
NCT00567424GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures
epilepsy · United StatesPHASE2
epilepsy · United StatesPHASE2
NCT00579982An Open-Label Trial Measuring Satisfaction And Convenience Of Two Formulations Of Lamotrigine In Subjects With A Mood Disorder
other_psychiatry · United StatesPHASE3
other_psychiatry · United StatesPHASE3
NCT00516139Lamotrigine Extended-Release In Elderly Patients With Epilepsy
epilepsy · United StatesPHASE3
epilepsy · United StatesPHASE3
NCT00144872LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
epilepsy · United StatesPHASE1
epilepsy · United StatesPHASE1
NCT01431963Clinical Study of Lamotrigine to Treat Newly Diagnosed Epilepsy
epilepsy · JapanPHASE3
epilepsy · JapanPHASE3
NCT00104416Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures
epilepsy · United StatesPHASE3
epilepsy · United StatesPHASE3
NCT00412191Bioequivalence And Lack Of Food Effects Of 300mg Lamotrigine XR
epilepsy · GermanyPHASE1
epilepsy · GermanyPHASE1
NCT01376180Drug Use Investigation for LAMICTAL
epilepsy · COMPLETED
epilepsy · COMPLETED
NCT00937846Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study
alzheimers · United KingdomPHASE1
alzheimers · United KingdomPHASE1
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →